Exagen Inc. (XGN)
| Market Cap | 65.30M |
| Revenue (ttm) | 66.58M |
| Net Income (ttm) | -19.95M |
| Shares Out | 24.05M |
| EPS (ttm) | -0.93 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 87,522 |
| Open | 2.750 |
| Previous Close | 2.740 |
| Day's Range | 2.700 - 2.760 |
| 52-Week Range | 2.590 - 12.230 |
| Beta | 1.94 |
| Analysts | Strong Buy |
| Price Target | 8.86 (+226.34%) |
| Earnings Date | May 11, 2026 |
About XGN
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company’s lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CT... [Read more]
Financial Performance
In 2025, Exagen's revenue was $66.58 million, an increase of 19.65% compared to the previous year's $55.64 million. Losses were -$19.95 million, 32.0% more than in 2024.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for XGN stock is "Strong Buy." The 12-month stock price target is $8.86, which is an increase of 226.34% from the latest price.
News
Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026
CARLSBAD, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended March 31, 2026...
Exagen Earnings Call Transcript: Q4 2025
Record 2025 revenue grew nearly 20% to $66.6M, driven by 11% test volume growth and higher ASP. 2026 guidance targets $70–$73M revenue, with continued volume and ASP gains, and breakeven expected at ~$80M run rate, likely in 2027.
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results
Record full-year total revenue and AVISE® CTD average selling price New biomarkers and sales force expansion drove over 11% full-year test volume growth CARLSBAD, Calif., March 10, 2026 (GLOBE NEWSWIR...
Exagen Inc. to Participate in Upcoming Investor Conferences
CARLSBAD, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following investor con...
Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026
CARLSBAD, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended December 31, 20...
Exagen Inc. Announces Select Preliminary 2025 Financial Results
CARLSBAD, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced select preliminary unaudited financial results for the fourth q...
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
CARLSBAD, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following upcoming inve...
Exagen Earnings Call Transcript: Q3 2025
Record Q3 revenue and volume growth were driven by new biomarker launches and strong commercial execution, though ASP expansion was slower than expected due to payer challenges. Pharma services revenue surged, and the company remains on track for 2025 guidance, with cash flow positivity targeted at the high end.
Exagen Inc. Reports Strong Q3 2025 Results
CARLSBAD, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, ...
Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence
CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of six abstracts at the 2025 American College of...
Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025
CARLSBAD, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended September 30, 2...
Exagen Inc. to Participate in Third Quarter Investor Conferences
CARLSBAD, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, today announced that management will participate in the following up...
Exagen Earnings Call Transcript: Q2 2025
Record Q2 revenue and volume growth were driven by new biomarkers, commercial execution, and expanding clinical adoption. Gross margin and ASP improved, with full-year revenue guidance of $65–$70 million and positive adjusted EBITDA expected by Q4 2025.
Exagen Inc. Reports Strong Q2 2025 Results
CARLSBAD, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2025,...
Exagen Inc. Appoints Chas McKhann to Board of Directors
CARLSBAD, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing solutions, announced today the appointment of Chas McKhann to its Boa...
Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025
CARLSBAD, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2025, ...
Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics
CARLSBAD, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, is pleased to announce the appointment of Dr. Michael Mahler as Chie...
Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares
CARLSBAD, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has completed the sale of an additional 502,50...
Exagen Inc. Prices Public Offering of Common Stock
CARLSBAD, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of its previously announced underwritten p...
Exagen Inc. Announces Proposed Public Offering of Common Stock
CARLSBAD, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has commenced an underwritten public offering ...
Exagen Earnings Call Transcript: Q1 2025
Record Q1 revenue and ASP growth were driven by new biomarker launches and increased test volume. Gross margin is expected to improve as new pricing is fully implemented, and the company is on track for positive Adjusted EBITDA by Q4 2025.
Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume
CARLSBAD, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2025,...
Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors
$25 Million Funded at Close to Refinance Existing Debt and Extend Maturity Additional Borrowing Capacity Provides Minimally Dilutive Growth Capital CARLSBAD, Calif., April 28, 2025 (GLOBE NEWSWIRE) --...
Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025
CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2025, before th...
Exagen Earnings Call Transcript: Q4 2024
Record 2024 revenue of $55.6M was driven by higher ASP and new biomarker launches, with gross margin nearing 60% and adjusted EBITDA loss improving 40%. 2025 guidance anticipates further revenue and margin growth, sales expansion, and positive adjusted EBITDA by Q4.